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Abstract  
Purpose. Use of complementary and alternative medicine (CAM) is common among 
breast cancer patients, but less is known about whether CAM influences breast cancer 
survival. 
Methods. Health Eating, Activity and Lifestyle (HEAL) Study participants (n=707) were 
diagnosed with stage I-IIIA breast cancer. Participants completed a 30-month post-
diagnosis interview including questions on CAM use (natural products such as dietary 
and botanical supplements, alternative health practices and alternative medical 
systems), weight, physical activity and co-morbidities. Outcomes were breast cancer-
specific and total mortality, which were ascertained from the Surveillance Epidemiology 
and End Results registries in Western Washington, Los Angeles County and New 
Mexico. Cox proportional hazards regression models were fit to data to estimate hazard 
ratios (HR) and 95% confidence intervals (CI) for mortality. Models were adjusted for 
potential confounding by sociodemographic, health and cancer-related factors.  
Results. Among 707 participants, 70 breast cancer-specific deaths and 149 total deaths 
were reported. 60.2% of participants reported CAM use post-diagnosis. The most 
common CAM was natural products (51%) including plant-based estrogenic 
supplements (42%). Manipulative and body-based practices and alternative medical 
systems were used by 27% and 13% of participants, respectively. No associations were 
observed between CAM use and breast cancer-specific (HR=1.04, 95% CI 0.61-1.76) or 
total mortality (HR=0.91, 95% CI 0.63-1.29).  
Conclusion. CAM use was not associated with breast cancer-specific mortality or total 
mortality. Randomized controlled trials may be needed to definitively test whether there 
is harm or benefit from the types of CAM assessed in HEAL in relation to mortality 
outcomes in breast cancer survivors. 
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Introduction  
 
 Over 230,000 women are diagnosed with breast cancer annually in the United 
States [1]. Many of these patients are eager to make lifestyle changes to improve their 
overall health and to increase the probability of long-term survival [2-5]. One common 
health/lifestyle behavior adopted by breast cancer patients is the use of complementary 
and alternative medicine (CAM) both during and after cancer treatment [6]. At the time 
of our study, the National Institutes of Health (NIH) National Center for Complementary 
and Alternative Medicine (NCAAM) (now called the National Center for Complementary 
and Integrative Health) (http://nccih.nih.gov) defined CAM as those practices or 
products that are typically “outside” of conventional or mainstream medical practice. The 
NIH definition included several broad categories of CAM such as natural products 
(dietary supplements, herbals and other botanical products), mind-body medicine (e.g., 
meditation, hypnosis, guided imagery), movement therapies, manipulative/body 
therapies (e.g., spinal manipulations, massage therapies, yoga) and energy practices 
(e.g., qi gong). Previous studies have reported that 50-75% of breast cancer patients 
use at least one form of CAM after diagnosis [7-10], with many patients attributing their 
overall good health, improved symptom management and well-being to use of CAM 
[11,12]. 
Several reports have described patterns of CAM use among breast cancer 
patients, particularly use of natural products and specific dietary supplements [6,9,12-
14].  However, few data exist on associations of CAM treatments with breast cancer 
survival. This is an important gap in the literature given the high prevalence of use and 
the strong belief by many patients that CAM improves their health [9,12]. However, it is 
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unknown whether CAM treatments have either positive or negative influences on 
prognosis, either through direct effects on the tumor biology, or indirect effects on 
patient response to treatment. For example, some botanical supplements have 
estrogenic effects [15,16], which may either raise or lower serum hormone 
concentrations, potentially affecting the growth of hormone sensitive estrogen receptor 
positive tumors. The primary objective of this study was to investigate associations of 
CAM use with breast cancer-specific mortality and total mortality in a cohort of breast 
cancer survivors.  
Materials and Methods 
 
The Health, Eating, Activity and Lifestyle (HEAL) study is a multicenter, 
multiethnic prospective cohort study of 1,183 breast cancer patients designed to 
determine whether weight, physical activity, diet, sex hormones, and other exposures 
influence breast cancer prognosis and survival. Details of the study design and 
procedures have been previously published [17]. Briefly, we utilized the National Cancer 
Institute’s Surveillance, Epidemiology, End Results (SEER) registries in New Mexico, 
Los Angeles County (CA), and Western Washington State to ascertain and recruit 
English speaking women diagnosed with in situ to Stage IIIA breast cancer. In New 
Mexico, we recruited 615 women aged 18 years or older diagnosed between July 1996 
and March 1999 and living in Bernalillo, Santa Fe, Sandoval, Valencia, or Taos 
Counties. In Western Washington State, we recruited 202 women between the ages of 
40 and 64 years diagnosed between September 1997 and September 1998 and living in 
King, Pierce, or Snohomish Counties. In Los Angeles County, we recruited 366 African-
American women who had previously participated in one of two cancer case-control 
5 
 
studies. These women were diagnosed with breast cancer between May 1995 and May 
1998 and were aged 35 to 64 years at diagnosis. Written informed consent was 
obtained from all participants at each study site. All HEAL procedures were approved by 
the institutional review boards of the participating centers (Fred Hutchinson Cancer 
Research Center, University of Southern California, University of New Mexico, City of 
Hope and University of Louisville) in accord with an assurance filed with and approved 
by the U.S. Department of Health and Human Services [17]. 
HEAL participants completed extensive questionnaires and health assessments 
within their first year after diagnosis (on average 7.5 months post-diagnosis). 
Information on health habits, medical history, history of breast disease, and reproductive 
history were collected via in-person interviews and self-administered questionnaires. 
Approximately 24 months later (within the third year after diagnosis and on average 
31.5 months post-diagnosis; hereafter called the 30-month post-diagnosis assessment), 
clinic or in-home visits were conducted to measure height and weight and to collect self-
reported data on physical activity, diet, dietary supplements (including herbal and 
botanical products), complementary and alternative medicine practices and use of 
alternative providers, and alcohol and tobacco use. Of the 1,183 eligible women, 239 
(20.2%) women did not complete the 30-month assessment due to death (n=44), illness 
(n=2), refusal (n=105), relocation (n=16), or loss to follow-up (n=72). Of the remaining 
944 participants, we excluded women with: (1) an initial breast cancer diagnosis of in 
situ disease (n=206) given their low risk of mortality [18]; (2) missing data on use of any 
complementary or alternative medicine (n=18); (3) an unknown date for subsequent 
breast cancer outcome or interview (n=5); or (4) a recurrence, second primary breast 
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cancer or death prior to the 30-month assessment (n=27).  The final sample included 
706 women who had an initial diagnosis of stage I to IIIA breast cancer and who 
completed the 30-month post-diagnosis assessment.  
Exposure Assessment for Complementary and Alternative Medicine (CAM) 
Four categories of CAM were defined as follows: (1) mind and body medicine 
(e.g., meditation, yoga, acupuncture, guided imagery, qi gong); (2) manipulative and 
body-based practices (e.g., spinal manipulation, massage therapy, chiropractic 
medicine); (3) alternative systems (e.g., traditional Chinese medicine, Native American 
healing systems, Reiki, homeopathic medicine, Ayurveda) and (4) natural products 
(e.g., herbal supplements, botanical supplements, single supplements and 
combinations of vitamins or minerals). Data for the first three categories (mind-body 
medicine, manipulative and body-based practices and alternative systems) were 
obtained from the following question on the 30-month assessment: “Have you sought 
out any type of complementary care?” If yes, 12 specific binary (yes/no) options were 
provided: hydrotherapy, herbal therapy, naturopathy, Chinese medicine, shiatsu, 
Ayurveda, homeopathy, acupuncture, acupressure, spiritual healing (new age) and 
prayer. In addition to this closed-ended response list, participants were permitted to list 
up to three additional types of complementary care or health practices (excluding 
natural products) as open-ended text fields. We recoded these responses into the three 
categories (mind-body; manipulative and body-based; and alternative systems). For 
example, meditation was re-coded in the “mind-body” category. 
To create the CAM category for natural product use, we used the responses from 
a question that asked participants whether they had used dietary supplements, herbal 
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and alternative remedies since the diagnosis. For dietary supplements, the following 12 
response categories were provided as yes/no responses: multivitamins, vitamin A, 
vitamin C, vitamin D, vitamin E, beta-carotene, melatonin, co-enzyme Q, alpha-lipoic 
acid, calcium, DHEA and fiber.  For herbal or alternative remedies, 34 specific response 
options (yes/no) were provided (e.g., bee pollen, black cohosh, blue cohosh, ginseng, 
shark cartilage). Open-ended text fields for other herbal and alternative remedies were 
permitted. All text fields (n=454 vitamins and minerals and n= 80 herbals and 
botanicals) were recoded into the variable “natural products.” Text fields where the 
response was unintelligible, not an alternative medicine (e.g., “Ensure®”, culinary spices 
such as cayenne pepper) or without sufficiently detailed information (“an alternative 
therapy”) were not counted as natural products and not included in these analyses. 
Although a large number of natural products were reported by HEAL participants, there 
were too few reports of any one particular type of product (e.g., cat’s claw, blue cohosh) 
to warrant the creation of single product variables, with the exception of botanical 
supplements with estrogenic properties, a subclass of natural products, which we had 
previously defined [19,20]. Estrogenic supplements were those with any reported 
estrogenic activity as documented in the Physician’s Desk Reference for Herbal 
Medicines (PDR-H) [21], Herb-Drug Interactions in Oncology [22] and the Natural 
Medicines Comprehensive Database (NMCD) [23].  
Outcomes Ascertainment  
To obtain the breast-cancer specific mortality and total mortality outcomes, 
women were followed for vital status from the 30-month post-diagnosis assessment until 
December 31, 2010 using data collected by the SEER registries and supplemented by 
abstracted medical records. Causes of death were classified using the International 
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Classification of Diseases, 10th Revision (ICD-10) codes. The time frame for overall 
mortality and breast-cancer specific mortality was initiated on the date of the 30-month 
post-diagnosis assessment and ended on the date of death.  All non-deceased 
participants were censored on December 31, 2010. 
Statistical Analyses  
Descriptive statistics were used to characterize the study sample. Cox 
proportional hazards models were fit to the data using age as the underlying time 
metric. We estimated hazard ratios (HR) and their 95% confidence intervals (CI) for 
death from any cause and death from breast cancer that was associated with: (1) any 
CAM use combining all four CAM categories;  (e.g., mind and body medicine, 
manipulative and body-based practices, alternative systems and natural products); (2) 
use of any natural products since it was the most common type of CAM; and (3) use of 
botanical-based estrogenic supplements since these products composed 80% of the 
natural product category and their use may have biological relevance for survival after a 
diagnosis of an estrogen-receptive positive tumor. There were too few instances of 
alternative systems or providers to assess as single exposure categories. Unadjusted 
models were analyzed along with models that included the following a priori covariates 
associated with breast cancer outcomes in HEAL [24-26] : breast cancer treatment 
(surgery, chemotherapy, radiation), stage at diagnosis (localized, regional, distant), 
reported use of tamoxifen (yes, no) at the 30-month interview, the Charlson co-morbidity 
score [27], body mass index (BMI) at 30-months post-diagnosis [computed as 
weight(kg)/height(m)2 and categorized into underweight (BMI<18.5), normal weight (BMI 
18.5-24.9), overweight (BMI 25.0-29.9 and obese BMI > 30.0)], 30-month assessment 
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of physical activity (mean MET-hours per week of sport and recreational exercise 
activity) and race/ethnicity. Since age was the time metric in the Cox models, it was not 
included as an additional covariate. All statistical tests were two sided and the 
significance level was set at α=0.05. The Statistical Analysis Software (SAS version 9.2, 
SAS Institute, Cary, NC) was used for all analyses.  
RESULTS 
The average age of HEAL Study participants at the time of the 30-month post-
diagnosis assessment was 57.4 years (Table 1). Slightly over one third (34.7%) of 
women were normal weight (BMI 18.5-24.9 kg/m2) and 28.0% and 28.7% were 
overweight (BMI=25.0-29.9 kg/m2) or obese (BMI > 30.0 kg/m2), respectively. Most 
participants (71.0%) had been diagnosed with localized disease (Stage I-II) and slightly 
over half (51.3%) reported tamoxifen use (aromatase inhibitors were not in clinical use 
at study onset). Approximately 60% of HEAL participants reported at least one type of 
CAM use since their breast cancer diagnosis (Table 2). The most commonly reported 
type of CAM, natural products, was used by 51% of participants who were CAM users. 
Manipulative and body-based practices, such as massage therapy and hydrotherapy 
were used by 27% of participants while mind-body therapies were used by only 4% of 
participants. Alternative medical systems such as naturopathy, Chinese medicine, 
Ayurveda and homeopathy were used by 13% of participants.  
 No associations were observed between CAM use or subtypes of CAM use and 
either breast cancer-specific mortality or total mortality (Table 3). The multivariate 
adjusted hazard ratios for any CAM use versus no use were 1.04 (95% CI 0.61-1.76) 
and 0.91 (95% CI 0.63-1.29) for breast cancer-specific and total mortality, respectively. 
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We also found no association of natural product use (vs. no natural product use) with 
either breast cancer-specific mortality (HR=1.15, 95% CI 0.69-1.94) or total mortality 
(HR=0.95 95% CI 0.67-1.35) (Table 4). Use of botanically-based estrogenic 
supplements vs. no use of these supplements was not associated with either breast 
cancer-specific mortality (HR =0.96, 95% CI 0.58-1.59) or total mortality (HR=0.84, 95% 
CI 0.57-1.23). In additional analyses, stratified by tumor hormone receptor status 
(ER+/ER-), results did not differ and were uniformly null (data not shown). 
DISCUSSION 
 In this cohort of breast cancer survivors, the use of complementary and 
alternative medicine was common, particularly the use of natural products. This finding 
of common usage is consistent with previous reports and confirms the widespread 
practice of CAM use by breast cancer patients [28-30]. Our principal finding was that 
overall CAM, natural products and botanically-based estrogenic supplements were not 
associated with breast cancer-specific or total mortality. Although used by many 
patients, CAM use remains controversial in the oncology community [31]. One end of 
the clinical advice spectrum supports a view that patients should not use any CAM, 
particularly natural products. This view is based on a concern that such products will 
either interfere with medical treatments or fuel residual hormone-sensitive tumors in the 
case of products with weak estrogenicity [32]. Other clinical views support the use of 
many CAM modalities by their patients [10]. However, no consensus statement has 
been formulated to date, due in part to a weak evidence base. A 2014 systematic 
review was conducted to inform clinical practice guidelines for use of integrative 
therapies for breast cancer patients [33]. An expert panel examined the strength of the 
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evidence base of clinical trials testing various modalities (e.g., natural products, mind 
body practices) and their efficacy for treatment and management of cancer treatment 
related symptoms, physical functioning and quality of life. The panel concluded that 
there was strong evidence (Grade A) that behavioral therapies such as meditation and 
hypnosis could improve depression, mood and quality of life/physical functioning. 
Moderate (Grade B) evidence supported the efficacy of yoga, meditation and massage 
for anxiety, stress reduction, depression/mood and nausea/vomiting. Most other 
modalities, including the small number of trials testing natural products for prevention or 
treatment of cancer related symptoms or treatment side effects in breast cancer patients 
received Grades C or D indicating either very small or no benefit. The expert panel 
recommended that more clinical trials are needed to test various CAM-type modalities in 
breast cancer patients in order to better inform patient and practitioner decisions.  
 Long-term survival of women with hormone sensitive breast cancer is improved 
substantially by the use of aromatase inhibitors and tamoxifen [34-36]. It is not known 
whether estrogenic botanical supplements function in a similar or different manner from 
these drugs [15,19,37-39]. Based on our previous finding that HEAL participants who 
used estrogenic supplements had significantly lower concentrations of estrone, 
estradiol, free estradiol and dehydroepiandrosterone sulfate (DHEAS) compared to 
participants not using these supplements [19], we anticipated an inverse association of 
estrogenic supplements with breast cancer-specific and total mortality. However, the 
findings we reported here were null. One possible explanation for the lack of association 
with mortality is that we have no data on long-term estrogenic supplement use since we 
only assessed use at one point in time, and we have limited data on duration of use. It is 
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possible that participants who reported estrogenic supplement use at the 30-month 
post-diagnosis assessment may not have maintained use on a long-term basis. As a 
result, the influence of estrogenic supplements on breast cancer-specific and total 
mortality may not have been reliably estimated. It is also possible that women with lower 
concentrations of sex hormones chose to use estrogenic supplements, perhaps 
because of increased postmenopausal symptoms, such as vasomotor symptoms or 
poor sleep quality.  
The lack of association between estrogenic supplement use and survival may be 
noteworthy since use of these products is common among breast cancer patients 
[40,41]. At the same time concern exists in the medical community about whether 
breast cancer patients should use these botanically based supplements with estrogenic 
properties [32]. Some recommendations state that breast cancer patients should not 
consume soy-containing foods or supplements out of concern that the weak estrogenic 
properties may fuel the growth of residual disease [37-39].  Our results suggest that use 
of estrogenic supplements neither increases nor decreases risk of breast cancer-
specific or total mortality in breast cancer survivors. These findings are consistent with 
those from two other cohort studies of breast cancer survivors, which reported that soy-
containing foods were not harmful to breast cancer patients and may be associated with 
improved survival [42,43]. 
While numerous investigations have reported on the prevalence of CAM use by 
breast cancer patients 6,9,12,44 only a few previous studies have examined the 
association between specific CAM categories, primarily natural product use, and 
mortality outcomes.  The Life After Cancer Epidemiology (LACE) cohort of 2,264 
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patients with early stage breast cancer (stage I-IIIA at diagnosis) examined dietary 
supplement use and survival [45].  Comprehensive data were collected on average 1.9 
years post-diagnosis and included data on antioxidants and other dietary supplements, 
but use of botanical/herbal preparations or other forms of CAM was not assessed. Use 
of vitamin E supplements after breast cancer diagnosis among LACE participants was 
associated with a lower risk of total mortality compared to no use after diagnosis (HR = 
0.76, 95% CI 0.58-1.0), whereas use of carotenoid supplements was associated with 
hazard ratios of 2.07 (95% CI 1.21-3.56) and 1.75 (95% CI 1.13-2.71) for breast cancer-
specific and total mortality, respectively [45]. The Shanghai breast cancer survival 
cohort also assessed antioxidant supplement use in relation to survival among 4877 
survivors. Compared to survivors who did not use supplements, those who used 
antioxidant-containing supplements with vitamin C or vitamin E had a total mortality 
hazard ratio of 0.82 (95% CI 0.65-1.02) [46]. In a Swedish cohort of 855 breast cancer 
patients, 58% of patients reported use of over 100 various types of dietary supplements. 
However, use of these supplements was not associated with survival (HR=0.78, 95% CI 
0.44-1.37) [47]. Finally, a small study of 61 patients who used alternative therapies 
instead of conventional medical treatment had very poor outcomes. Over 96% of these 
patients who chose to forego standard medical therapy, and instead relied exclusively 
on CAM experienced disease progression and 51% died after a median follow-up of 54 
months [48]. None of these studies, including HEAL, examined whether specific 
categories of CAM, other than natural products, influenced survival, partly due to low 
numbers of use for any one particular modality (e.g., Chinese medicine, Ayurveda).  
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This study has several strengths. The HEAL Study was one of the earliest breast 
cancer survivor cohorts to be established; it has been in place since 1997 and we have 
tracked vital status through the SEER registries and the National Death Index. Another 
strength is that HEAL collected comprehensive data on complementary and alternative 
medicine, including the names of specific natural products and estrogenic supplements 
whereas many studies have collected these using a binary (yes/no) question to assess 
“any use” of CAM [6,9] . HEAL also has breast cancer treatment data collected by 
abstracting medical records in addition to the SEER registry data.  
This study also has limitations. While we obtained data on self-reported use of 
natural products, it is not possible to collect dosage information due to the lack of 
uniformity in the manner in which these products are formulated in the United States 
[49]. Further, supplements sold in the U.S. are not governed for consistency of product 
formulation or dosage consistency. Without certainty about product ingredients it is 
difficult to determine how they influence outcomes. Another limitation is that we were 
unable to analyze data for individual supplements, such as black cohosh, because the 
number of participants taking any one specific supplement was too small. In addition, 
tumor estrogen receptor status was not available for 11% of participants because either 
the test was not conducted (n=13), the test result was not in medical chart (n=34) or the 
reason the test was missing was unknown (n=25). Sample size for analyses by tumor 
hormone receptor status was limited. More contemporary classifications such as luminal 
A, luminal B and basal-like subtypes are not available in HEAL. Finally, HEAL has more 
extensive and lengthy follow-up than some other cohorts [30,45,46], but the number of 
breast cancer-specific and total deaths was small and therefore our analyses lack 
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statistical power. Our results should therefore be interpreted with caution. Finally, as in 
all observational studies, residual confounding may have occurred in the HEAL Study 
as a result of measuring some variables imprecisely or not including an important 
covariate. Definitive information on effects of CAM on breast cancer survival would 
require data from placebo-controlled, randomized controlled trials. Outcomes for most 
trials have been focused on symptoms and side effects of breast cancer treatment such 
as fatigue, anxiety, sleep, quality of life, physical functioning and various physical 
symptoms [16,33]. Clinical trials are needed to test the efficacy of and to evaluate the 
overall risks and benefits of various CAM modalities in relation to breast cancer survival. 
 In conclusion, use of complementary and alternative medicine, natural products 
and botanically-based estrogenic supplements was not associated with risk of breast 
cancer-specific or total mortality in this cohort of breast cancer survivors. Future 
research with comprehensive measurements of CAM use including duration and dose 
(where possible) in larger cohorts of breast cancer patients with data on molecular 
subtyping of tumors is needed to explore potential relationships between specific 
supplements or therapies and outcomes, as well as any interactions between CAM use 
and conventional treatments. 
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Table 1. Characteristics of Breast Cancer Survivors in the Health Eating Activity and 
Lifestyle (HEAL) Study (n=707) 
 Mean SD 
Age (mean, SD) 57.9 10.7 
Weekly MET-hours of sport and 
recreational activity (mean SD) 
12.8 19.2 
 n % 
Body Mass Index (kg/m2)1 
  <18.5 (n, %) 
  18.5-24.9 
  25.0-29.9 
  > 30.0 
 
16 
245 
198 
203 
 
2.3 
34.7 
28.0 
28.7 
Current smoker 88 12.4 
Race/Ethnicity 
  Non-Hispanic white 
  Black/African-American 
  Hispanic 
  Other2 
 
403 
199 
87 
18 
 
57.0 
28.2 
12.3 
2.5 
Current use of tamoxifen 363 51.3 
SEER stage of disease at diagnosis 
  Localized 
  Regional 
 
502 
205 
 
71.0 
29.0 
Tumor estrogen receptor status 
  ER positive 
  ER negative 
  Other/unknown 
 
488 
143 
  76 
 
69.1 
20.2 
10.6 
Breast cancer treatments 
  Surgery only 
  Surgery + radiation 
  Any chemotherapy 
 
172 
250 
285 
 
24.3 
35.4 
40.3 
1. n=45 participants are missing BMI values 
2 Includes American Indian (n=5), Asian or Pacific Islander (n=11), unknown or not specified 
(n=2) 
Abbreviations: SD, standard deviation; SEER, Surveillance, Epidemiology and End Results; ER, 
estrogen receptor 
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Table 2. Complementary and Alternative Medicine (CAM) Use by Health, Eating, Activity 
and Lifestyle (HEAL) Participants1  
Type of Complementary and Alternative 
Medicine 
n % 
Any CAM 426 60.2 
Mind-Body Medicine2   31   4.4 
Manipulative and Body-based Practices3 192 27.2 
Alternative Systems4   94 13.3 
Natural Products5 363 51.3 
  Estrogenic Supplements6 294 41.6 
1.  Groupings based on NIH’s National Center for Complementary and Alternative Medicine (NCAAM) 
classifications (see methods section for details) 
2.  Examples include meditation, yoga, guided imagery, qi gong 
3.  Examples include spinal manipulation, massage therapy, chiropractic medicine 
4.  Examples include Chinese medicine, Reiki and Ayurveda 
5.  Dietary supplements of vitamins, minerals, herbals and botanicals 
6.  Estrogenic supplements are a subset of the category natural products 
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Table 3. Associations of use of complementary and alternative medicine with risk of 
breast cancer-specific mortality and total mortality in breast cancer survivors 
Use of any complementary or alternative 
medicine 
   
Outcomes No. of 
deaths 
HR 95% CI 
Breast cancer specific mortality    
  Unadjusted 70 0.80 0.50-1.28 
  Multivariable1 70 1.04 0.61-1.76 
Total mortality    
  Unadjusted 149 0.70 0.50-0.96 
  Multivariable1 149 0.91 0.63-1.29 
1. Adjusted for race/ethnicity, BMI, stage of disease, breast cancer treatment, tamoxifen use, 
Charlson co-morbidity score, weekly MET-hours of physical activity
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Table 4. Associations of use of natural products with risk of breast cancer-specific 
mortality and total mortality in breast cancer survivors 
Use of Natural Products    
Outcomes No. of deaths HR 95% CI 
  Breast cancer-specific mortality    
    Unadjusted 70 0.88 0.55-1.41 
    Multivariable1 70 1.15 0.69-1.94 
  Total mortality    
    Unadjusted 149 0.73 0.53-1.02 
    Multivariable1 149 0.95 0.67-1.35 
    
Use of Estrogenic Supplements     
  Breast cancer-specific mortality    
    Unadjusted 70 0.87 0.53-1.41 
    Multivariable1 70 0.96 0.58-1.59 
  Total mortality    
    Unadjusted 149 0.69 0.48-1.00 
    Multivariable1 149 0.84 0.57-1.23 
1. Adjusted for race/ethnicity, BMI, stage of disease, breast cancer treatment, tamoxifen use, 
Charlson co-morbidity score, weekly MET-hours of sport and recreational physical activity 
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